Moreover, effects like an enhanced cross-priming of naïve CD8+ T cells by dendritic cells (50), upregulation of CD80 on tumor cells correlating with T cell activation (51) and a reversal of impaired immunological synapse formation of T cells in CLL patients (52) make lenalidomide a promising adjuvant to improve peptide-specific T cell induction. This evidence concerns the gene CD80 and B-cell chronic lymphocytic leukemia.